JP3843260B2 - 誘導適合を含めたタンパク質の立体構造構築方法およびその利用 - Google Patents
誘導適合を含めたタンパク質の立体構造構築方法およびその利用 Download PDFInfo
- Publication number
- JP3843260B2 JP3843260B2 JP2002558170A JP2002558170A JP3843260B2 JP 3843260 B2 JP3843260 B2 JP 3843260B2 JP 2002558170 A JP2002558170 A JP 2002558170A JP 2002558170 A JP2002558170 A JP 2002558170A JP 3843260 B2 JP3843260 B2 JP 3843260B2
- Authority
- JP
- Japan
- Prior art keywords
- dimensional structure
- protein
- ligand
- target protein
- atomic coordinates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 287
- 108090000623 proteins and genes Proteins 0.000 title claims description 287
- 238000010276 construction Methods 0.000 title claims description 27
- 230000001939 inductive effect Effects 0.000 title claims description 13
- 230000006978 adaptation Effects 0.000 title description 2
- 239000003446 ligand Substances 0.000 claims description 165
- 238000000034 method Methods 0.000 claims description 130
- 238000004364 calculation method Methods 0.000 claims description 71
- 238000004458 analytical method Methods 0.000 claims description 33
- 238000003032 molecular docking Methods 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 238000005381 potential energy Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 238000012935 Averaging Methods 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 84
- 125000004429 atom Chemical group 0.000 description 81
- 108090000631 Trypsin Proteins 0.000 description 37
- 102000004142 Trypsin Human genes 0.000 description 37
- 239000012588 trypsin Substances 0.000 description 35
- 230000006870 function Effects 0.000 description 34
- 101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 31
- 239000003814 drug Substances 0.000 description 26
- 239000012454 non-polar solvent Substances 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 238000000329 molecular dynamics simulation Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000005457 optimization Methods 0.000 description 19
- 150000003384 small molecules Chemical class 0.000 description 18
- 239000003905 agrochemical Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000006399 behavior Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 238000002441 X-ray diffraction Methods 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 8
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000003125 aqueous solvent Substances 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 238000002922 simulated annealing Methods 0.000 description 7
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 6
- 102000004330 Rhodopsin Human genes 0.000 description 6
- 108090000820 Rhodopsin Proteins 0.000 description 6
- 101710162629 Trypsin inhibitor Proteins 0.000 description 6
- 229940122618 Trypsin inhibitor Drugs 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000007621 cluster analysis Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000000737 periodic effect Effects 0.000 description 6
- 239000002753 trypsin inhibitor Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000000324 molecular mechanic Methods 0.000 description 5
- 238000002424 x-ray crystallography Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 244000018633 Prunus armeniaca Species 0.000 description 4
- 235000009827 Prunus armeniaca Nutrition 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002939 conjugate gradient method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 238000002940 Newton-Raphson method Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000361 pesticidal effect Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 238000012887 quadratic function Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000012872 agrochemical composition Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000012617 force field calculation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001011783 | 2001-01-19 | ||
JP2001011783 | 2001-01-19 | ||
PCT/JP2002/000286 WO2002057954A1 (fr) | 2001-01-19 | 2002-01-17 | Procede pour realiser une structure tridimensionnelle de proteine avec ajustement induit et son utilisation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006013792A Division JP4315960B2 (ja) | 2001-01-19 | 2006-01-23 | タンパク質のリガンド結合部位の特定方法およびタンパク質−リガンド複合体の立体構造構築方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2002057954A1 JPWO2002057954A1 (ja) | 2004-09-16 |
JP3843260B2 true JP3843260B2 (ja) | 2006-11-08 |
Family
ID=18878877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002558170A Expired - Fee Related JP3843260B2 (ja) | 2001-01-19 | 2002-01-17 | 誘導適合を含めたタンパク質の立体構造構築方法およびその利用 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP3843260B2 (fr) |
WO (1) | WO2002057954A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4314128B2 (ja) * | 2004-02-24 | 2009-08-12 | 株式会社インシリコサイエンス | タンパク質立体構造と誘導適合を利用したリガンド探索方法 |
WO2005114458A1 (fr) * | 2004-05-06 | 2005-12-01 | Sarnoff Corporation | Sondage informatique de proteines pour identifier des sites de liaison |
JP2007219760A (ja) * | 2006-02-15 | 2007-08-30 | Fujitsu Ltd | ドッキングシミュレーションプログラム、該プログラムを記録した記録媒体、ドッキングシミュレーション装置、およびドッキングシミュレーション方法 |
JP5942571B2 (ja) * | 2012-04-27 | 2016-06-29 | 富士通株式会社 | 計算支援プログラム、計算支援装置、および計算支援方法 |
EP3026588A1 (fr) * | 2014-11-25 | 2016-06-01 | Inria Institut National de Recherche en Informatique et en Automatique | Paramètres d'interaction pour l'ensemble d'entrée de structures moléculaires |
CN107480429B (zh) * | 2017-07-21 | 2020-07-03 | 清华大学深圳研究生院 | 化合物的3d展示方法和系统 |
JP6995990B2 (ja) * | 2018-06-06 | 2022-02-04 | 株式会社日立製作所 | タンパク質相互作用解析装置及び解析方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013785A1 (fr) * | 1994-10-31 | 1996-05-09 | Akiko Itai | Procede pour extraire de nouveaux composes ligands contenus dans une base de donnees a structure tridimensionelle |
-
2002
- 2002-01-17 JP JP2002558170A patent/JP3843260B2/ja not_active Expired - Fee Related
- 2002-01-17 WO PCT/JP2002/000286 patent/WO2002057954A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2002057954A1 (fr) | 2002-07-25 |
JPWO2002057954A1 (ja) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bakan et al. | Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules | |
Schmidtke et al. | Understanding and predicting druggability. A high-throughput method for detection of drug binding sites | |
JP4315960B2 (ja) | タンパク質のリガンド結合部位の特定方法およびタンパク質−リガンド複合体の立体構造構築方法 | |
Sadiq et al. | Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases | |
Raman et al. | Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach | |
von Korff et al. | Comparison of ligand-and structure-based virtual screening on the DUD data set | |
Giganti et al. | Comparative evaluation of 3D virtual ligand screening methods: impact of the molecular alignment on enrichment | |
Brown et al. | Large-scale application of high-throughput molecular mechanics with Poisson− Boltzmann surface area for routine physics-based scoring of protein− ligand complexes | |
US20030158672A1 (en) | Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics for drug design and clinical applications | |
Craig et al. | Pocket-space maps to identify novel binding-site conformations in proteins | |
Hoffer et al. | S4MPLE–sampler for multiple protein–ligand entities: Simultaneous docking of several entities | |
CA2542456A1 (fr) | Systeme d'optimisation et d'anticipation des reactions croisees de molecules amorces | |
Martinez-Rosell et al. | PlayMolecule CrypticScout: predicting protein cryptic sites using mixed-solvent molecular simulations | |
JP3843260B2 (ja) | 誘導適合を含めたタンパク質の立体構造構築方法およびその利用 | |
US7826979B2 (en) | Method of modeling complex formation between a query ligan and a target molecule | |
US20080319677A1 (en) | Systems and Methods for Designing Molecules with Affinity for Therapeutic Target Proteins | |
Hema et al. | Atomic resolution homology models and molecular dynamics simulations of Plasmodium falciparum tubulins | |
Durojaye et al. | Csc01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach | |
Stavrakoudis | Conformational flexibility in designing peptides for immunology: the molecular dynamics approach | |
Moon et al. | 3D database searching and de novo construction methods in molecular design | |
Markt et al. | Discovery of novel cathepsin S inhibitors by pharmacophore-based virtual high-throughput screening | |
Hoppe et al. | Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials | |
Rai et al. | Recent trends in in-silico drug discovery | |
US20060141480A1 (en) | Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics and clinical applications | |
Gadhe et al. | Binding site exploration of CCR5 using in silico methodologies: A 3D-QSAR approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20030723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20030723 |
|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20031021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20030723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060123 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060515 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060629 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060814 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120818 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130818 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130818 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130818 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |